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ABSTRACT
Sex differences in pain have been reported for over a half-century with males having
higher pain tolerance and lower pain sensitivity than females. Testosterone, a male
hormone, is associated with pain perception in humans. However, as of yet no study has
directly manipulated a participants’ testosterone to test for causal relationship between
testosterone and pain. A double-blind fully-crossed study was conducted using sublingual
administration of 0.5 mg testosterone. Twenty female participants completed two 5-hour
sessions over a 3-day period. Participants completed an ischemic pain task, behavioral
tasks and self-report measures at baseline and at post-administration to explore the effects
of testosterone intervention on self-perceived health, aggression, risk-taking, body selfesteem, self-perceived mate value, sexual attitudes, and disgust. Three multilevel models
were conducted to test how the drug intervention influenced levels of testosterone,
estradiol, and progesterone. Testosterone was significantly higher for females who
received the drug intervention as compared to females who received the placebo (p <
0.001). A significant interaction between time and intervention was also found for
estradiol (p < 0.001) and progesterone (p < 0.001) meaning that both hormones were
higher in females who received the testosterone intervention. Several one-way repeated
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measure analysis of variance (ANOVAs) were carried out to examine the remainder of
the outcome variables. Female participants given testosterone reported higher selfperceived physical functioning (p = 0.04) and exhibited higher risk-taking behavior when
performing the Balloon Analogue Risk Task BART (p = 0.03) than those who received
the placebo. However, testosterone did not influence the following variables: selfreported aggression, risk-taking behaviors, body image self-esteem, sexual attitudes, mate
value, and disgust behaviors (p > 0.05). These findings suggest that a single sublingual
administration of 0.5 mg testosterone is not powerful enough to alter pain perception in
female participants but is sufficient to alter levels of other sex hormones along with risktaking behavior and perceived physical functioning.
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Chapter 1: Introduction
Sex Differences
Sex differences are not uncommon among medical and psychological diseases.
There are several diseases and medical conditions such as temporomandibular joint
disorder (TJD), fibromyalgia, irritable bowel syndrome (IBS), and arthritis that appear
disproportionately more frequently in females than in males (Unruh, 1996). With IBS, for
example, the female to male patient population ratios can range from 3:1 to 5:1 in certain
patient populations (Heitkemper, Jarrett, Bond, & Chang 2003; Longstreth & WoldeTsadik, 1993; Toner & Akman, 2000). Symptom presentation of IBS can differ between
females and males, with females exhibiting more symptoms of constipation, bloating, and
severe abdominal pain while males may report diarrhea more often (Adeyemo, Spiegel,
& Chang, 2010; Chang et al., 2006; Lovell & Ford, 2012;). IBS provides an excellent
example of how a disease can appear more often in one sex and differ in its symptom
presentation between the sexes. Some autoimmune diseases are also more prevalent in
females than males, with more women suffering from Sjogren’s Syndrome, Systemic
Lupus Erythematosus, Multiple Sclerosis, thyroid disease, Sclerodema, and Rheumatoid
arthritis (Whitacre, 2001).
It has long been reported that females suffer from depression more often than
males (Radloff, 1975). A meta-analysis on sex differences in Post-Traumatic Stress
Disorder (PTSD) found that women reported more symptoms associated with PTSD;
however, they were less likely to experience a traumatic event (Tolin & Foa, 2006).
Autism, a developmental disease characterized by dearth of language and social skills,
has been found to be more common among boys than girls; however, there is evidence
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that girls suffer from more problems with language and exhibit more signs of anxiety and
depression related to autism (Hartley & Sikora, 2009). Taken together, stark sex
differences in medical and in psychological diseases illustrates the importance in
understanding sex differences in males and females. This is especially important when
considering sex differences in pain, which is not just a universal human experience but is
nearly universal in most animal species. Therefore, understanding the origins of sex
differences in pain can lead to better predictions on when sex differences will be more
pronounced and potentially lead to better diagnoses and treatments for pain.
Sex differences in pain have been observed numerous times within the pain
literature, with some of the first reported sex differences appearing over 40 years ago
(Notermans & Tophoff, 1967). Fillingim, King, Ribeiro-Dasilva, Rahim-Willimas, and
Riley III (2009), in a review of sex differences in pain, found that in the last 30 years the
literature of sex differences in pain has steadily increased starting in the mid-1990s. A
meta-analysis on experimental pain studies found medium to large effect sizes with
electrical, thermal, and pressure experimental pain paradigms indicating that men were
more tolerant of pain and less sensitive (Riley III, Robinson, Wise, Myers, & Fillingim,
1998).
Numerous explanations have been made to explain origin of sex differences in
pain. These differences include variations in brain morphology, genetics, social and
psychological contributions, and hormones. Each of these explanations will be reviewed
briefly, however, specific attention will be placed on hormones with an emphasis on
testosterone.
Brain Morphology
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Pain has been studied extensively in relation to brain morphology. The use of
neuroimaging techniques such as electroencephalogram (EEG), Functional magnetic
resonance imaging (fMRI), and positron emission tomography (PET) has lead researchers
to conclude that certain cortical and subcortical areas of the human brain are responsible
for the perception of pain. A meta-analysis performed on pain studies using
neuroimaging techniques found that the thalamus, insular, anterior cingulate cortex
(ACC), and the primary and secondary somatosensory areas were associated with the
perception of an acute pain experience (Apkarian, Bushnell, Treede, & Zubieta, 2005).
Pain, therefore, is a complex somatosensory process involving a network of several
cortical and subcortical areas of the brain, which has led to the proposal of a “Pain
Matrix” within the brain (Melzack, 1999). The Pain Matrix hypothesis for pain
processing posits that the sensory network for perceiving pain can be modulated by one
or several cortical areas. Yet, the exact interaction of this pain matrix and how the brain
integrates the information from the different cortical areas is still debated (Legrain,
Iannetti, Plaghki, & Mouraux, 2011; Tracey & Mantyh, 2007). Nevertheless, the
identification of specific regions of the brain has led to the analysis of these regions in
relation to sex differences in pain.
In humans, PET scans have shown that males had greater activation of the
primary and secondary somatosensory areas, the insula, and parietal cortices while
females showed greater activation in the perigenual cingulate cortex (Derbyshire,
Nichols, Firestone, Townsend, & Jones, 2002). A PET study on IBS patients used a
visceral pain stimulus (i.e., rectal inflation or catheter insertion) found that women had
greater activation in the ventromedial prefrontal cortex, right ACC, and left amygdala
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(Naliboff et al., 2003). On the other hand, men were found to have higher activation in
the dorsolateral prefrontal cortices (DLPFC), insula, and dorsal pons/periaqueductal gray.
Another PET scan study found that females had greater activation of the contralateral
prefrontal cortex in a thermal pain task than men (Paulson, Minoshima, Morrow, &
Casey, 1998). fMRI studies have also found sex differences in pain. For example, an
fMRI study examining muscle pain induced by a saline injection found that men had
greater activation in the mid-cingulate cortex and the DLPFC while females had greater
activation in the cerebellar cortex and an increase in activation in the hippocampus during
muscle pain and a decrease during cutaneous pain (Henderson, Gandevia, & Vaughan,
2008). Taken together, this body of research provides support to a neural origin to pain
differences based on sex. As Fillingim et al. (2009) notes, though, sex differences in brain
regions should be considered with caution since the pain induction techniques and the
brain imaging techniques vary from study to study.
Genetics
Genetic explanations for sex differences in pain are limited, with insufficient
support for genetic contributions in sex differences in pain. Several genes have been
identified in animal models and humans that are associated with the perception of pain
(see Foulkes & Wood, 2008 for a review). However, genetic explanations for sex
differences in pain are limited. One study has found a link between a specific gene and
sex differences in pain. The melanocortin-1 receptor (MC1R) is responsible for skin
pigmentation that when activated produces melanin in skin, but invariant (i.e., mutant)
versions of this gene produce light skin and red hair. In females who have this invariant
version, had increased sensitivity to pain and an increase in analgesic responsiveness,
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making them less sensitive to analgesics (Mogil et al., 2005). This finding presents new
research methods to understanding sex differences in pain and treating pain.
Social and Psychological Contributions
Gender roles. Despite the physiological, hormonal, and genetic differences that
have been reported, social and psychological influences have been found to modulate the
perception and expression of pain in humans. The use of the dichotomous variable “sex”
has been disputed in pain research in that its use is often confused with gender or social
roles in which masculinity and femininity are learned and reinforced in children at a
young age (Fillingim et al., 2009; Myers, Riley III, & Robinson, 2003). Sex differences
in pain, therefore, might be the result of males and females being socialized to react to
pain as expected of their gender role (i.e., boys do not cry and girls tell an adult).
Robinson et al. (2001) tested this assumption by developing the Gender Role
Expectation of Pain questionnaire (GREP) and found that men and women both reported
that men are expected to underreport their pain and that women are more sensitive and
less tolerant of pain than men. Another study found that when controlling for an
individual’s GREP score, sex differences were eliminated in pain sensitivity and pain
tolerance (Wise et al., 2002). It is important to note that when they performed
hierarchical regression analysis, sex difference was maintained even after controlling for
participants GREP scores. High self-reported masculinity by males correlated with higher
pain tolerance, but no such relationship was found in women (Otto & Dougher, 1985).
However, these results are not conclusive, with some studies reporting a relationship
between gender roles and pain, but gender roles were unable to explain the sex
differences (Myers, Robinson, Riley III, & Sheffield, 2001) and other findings showing
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no relationship between gender and pain (Fillingim, Edwards, & Powell, 1999).
Altogether, gender socialization should be considered when explaining sex differences in
pain.
Psychological Disorders. Psychological factors (i.e., depression/anxiety) have
also been found to contribute to sex differences in pain. Depression has been previously
found to exacerbate pain reports in experimental studies in that individuals suffering from
depression report more pain than individuals without depression (Bär et al., 2005;
Piñerua-Shuhaibar et al., 1999). This is important when considering sex differences in
pain because women are more often than men diagnosed with depression than men
(Munce & Steward, 2007), and women report more pain associated with their depression
than men (Marcus et al., 2008). How depression or mood might influence pain perception
and expression differently in men and women is not known (Fillingim et al., 2009).
However, differences in depression are no doubt important to understanding sex
differences in pain.
Anxiety is another mental illness that is diagnosed in women more than in men
(Regier et al., 1993). Women with high anxiety often report increased pain in both
experimental and clinical settings (Rhudy & Williams, 2005; Robin, Vinard, VernetMaury, & Saumet, 1987). Women who reported being victims of physical and/or sexual
abuse reported more somatic symptoms associated with pain (Riley III, Robinson, Kvaal,
& Gremillion, 1998). Therefore, the anxiety level of the participant, especially if they are
female, should be considered when studying sex differences in pain. Anxiety and
depression should be potentially controlled when analyzing these differences in pain.
However, depression and anxiety occur more often in females. Whether this is due to
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socialization or biology is debatable, but biological causes for sex differences should not
be completely ruled out.
Distraction and Coping Styles. Differences in distraction and coping styles have
been implicated in sex differences in pain. Distraction, or the focusing of the
participant/patient’s attention away from the painful stimulus, has been researched as a
potential aid to those that are experiencing pain. The belief is that if a participant/patient
is not focusing on the pain, then they will perceive the pain as being less intense.
Research on distraction is mixed. Several studies conducted using chronic pain
patients, patents undergoing a dental procedure, and normal college students have
showed that there is no effect for distraction when engaging in a pain task (Aitken,
Wilson, Coury, & Moursi, 2002; Goubert, Crombez, Eccleston, & Devulder, 2004;
McCaul, Monson, & Maki, 1992). However, an MRI study examining the Anterior
Cingulate Gyrus (ACG) found that when men and women engaged in a cold pressor task
while distracted reported their pain as being less intense (Frankenstein, Richter,
McIntyre, Rémy, 2001).
In another study, men who focused their attention on their pain as oppose to
avoiding their pain reported less pain intensity while no effect was found in women
(Keogh, Hatton, Ellery, 2000). This has led to further research demonstrating that men
and women differ in their coping strategies. Men who focus on their pain sensations
during a pain task feel less pain, but when focusing on the emotions they feel during a
pain task they feel more pain (Keogh & Herdenfeldt, 2002). The opposite pattern was
found with females, in that women who focused on the emotional component of pain
reported less pain and women who focused on the sensations reported more pain.
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In a chronic pain study with adolescents, males relied more on behavioral
distraction coping strategies whereas females relied more on social support and emotionfocused coping strategies (Keogh & Eccleston, 2006). Again, as with depression and
anxiety, it difficult to ascertain with certainty whether sex differences in distraction or
coping styles are the result of biology/socialization or an interaction of the two.
Hormones
Estrogen. Logically, hormone variations across the sexes have been used to
account for these differences. For example, estrogen has been implicated as pain pronociceptive agent. Several pain-inducing medical conditions (e.g. migraine headaches,
Temporomandibular Joint Dysfunction [TJD], Irritable Bowel Syndrome [IBS]) either
appear or worsen around puberty for females when estrogen level is naturally increased:
such conditions are mitigated after menopause when estrogen is naturally decreased
(Brandes, 2006; Mulak, Taché, & Larauche, 2014; Warren & Fried, 2001). The use of
oral contraception that promotes estrogen in the body has been found to be associated
with increased risk of TJD in females (LeResche, Saunders, Von Korff, Barlow, &
Dworkin, 1997). In a study looking at transgender females using a hormone replacement
therapy in the form of estrogen supplementation and anti-androgens, participants reported
increased pain associated with their chronic pain condition (Aloisi et al., 2007).
Estrogens appears to promote pain, but the male androgens, specifically,
testosterone appear to have the opposite effect, in that it dampens pain. It is therefore
important to focus on testosterone and its association with pain to better understand how
sex differences in pain may arise.
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Testosterone. In humans, testosterone has been linked to the initial
masculinization of the male brain (Morris, Jordan, & Breedlove, 2004) and further sexual
differentiation of males at puberty with the development of secondary sexual
characteristics (Hiort, 2002). Specifically, testosterone has been found to allocate energy
to the development/growth of muscle tissue and skeletal cells (Kasperk, Wergedal,
Farley, Linkhard, & Turner, 1989; Power & Florini, 1975).
Along with altering the physical appearance of males, testosterone also alters
behaviors. Testosterone has also been implicated in courtship/mating behaviors
(Hutchison, 1970; Lindzey & Crews, 1986; Wiley & Goldizen, 2003), territorial
aggression (Hau, Wikelski, Soma, & Wingfield, 2000; Soma, Sullivan, & Wingfield,
1999), ornamentation (Ligon, Thornhill, Zuk, & Johnson, 1990; Parker, Knapp, &
Rosenfield, 2002; Setchell, Smith, Wickings, & Knapp, 2008) and social rank (Muller &
Wrangham, 2004; Rose, Holaday, & Bernstein, 1971) in several species. In humans,
testosterone has been linked to dominant, antisocial, and aggressive behaviors (Archer,
2006; Mazur & Booth, 1998; Rowe, Maughan, Worthman, Costello, & Angold, 2004).
Testosterone and the immune system. Testosterone has been negatively
correlated with parenting effort, immunity, and overall survival (Sinervo & Svensson,
1998; Wingfield, Hegner, Dufty, & Ball, 1990). In male birds for example, testosterone is
at its highest during the mating season, and during this time the immune system is
compromised in males with higher instances of infection and greater vulnerability to
parasites (Deerenberg, Arpanius, Daan, & Bos, 1997; Owen-Ashley, Hasselquist,
Wingfield, 2004; Saino, Bolzern, Møller, 1997; Sheldon & Verhulst, 1996 Zuk &
Johnsen, 1998). The human immune system is also suppressed by the actions of
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testosterone (see Muehlenbein & Bribiescas, 2005 for a review). One study examined
males with higher fat-free mass and high limb muscle volume, which was previously
associated with attractiveness, and found that males had lower C-reactive protein and
white blood cell count (Lassek & Gaulin, 2009). Males given a flu vaccination had a
reduction of testosterone the weeks following the vaccination. Finally, Men with
respiratory infections or who had more flu/cold like symptoms were also found to have
lower testosterone (Gettler, McDade, Agustin, Feranil, & Kuzawa, 2014; Muehlenbein,
Hirschtick, Bonner, & Swartz, 2010). These studies provide evidence that, like with
birds, the human immune system is suppressed by the actions of testosterone.
Testosterone, has many pleiotropic effects on the human body with some of those
effects being beneficial to the individual (i.e., mating advantages), while others may be
detrimental (i.e., immune suppression). Again, testosterone allocates energy, and in males
mating effort is prioritized over the well-being of the body. It therefore stands to reason,
by the actions of testosterone, that pain is also being suppressed in males. It has been
recently argued that sex differences in pain might originate in differences in immune
system functioning between the sexes, which may be modulated by the expression of sex
hormones (see Rosen, Ham, & Mogil, 2017 for a review). Whether sex differences in
pain originate in the immune system is not quite known, but based on the actions of
testosterone on the immune system, it is important to know how testosterone modulates
other bodily functions, specifically pain.
Testosterone and pain. Several studies have been conducted using animal
models that have tested the role of testosterone and pain. In a study looking at
gonadectomized male rats and gonad intact male rats, gonad intact rats showed a
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decreased reaction (i.e., paw jerking, licking) after several formalin injections of
testosterone (pain induction task) whereas gonadectimized rats had an increased reaction
(Aloisi, Ceccarelli, Fiorenzani, De Padova, & Massafra, 2004; Ceccarelli, Scaramuzzino,
Massafra, Aloisi, 2003). Another study looking at rats found the expression of c-Fos was
unchanged in the hypothalamus, a region of the brain associated with pain, of the gonad
intact males whereas its expression was increased in gonadectomized male rats (Aloisi,
Ceccarelli, Fiorenzani, De Padova, & Massafra, 2004). In an experiment involving house
sparrows, males given exogenous testosterone held their feet in hot water longer than
controls but males who were given an androgen antagonist pulled their feet out much
sooner than controls (Hau, Dominquez, & Evrard, 2004). These studies provide support
that testosterone acts as an analgesic; animal models with higher testosterone than
controls are less likely to express painful behaviors. Evidence is also provided showing
that testosterone interacts with regions of the brain that are responsible for pain
perception.
In humans, research on testosterone and pain are limited; however, there have
been studies in clinical chronic pain and experimental acute pain that have found a link
between the two. People who use opioids for chronic pain or abuse opioids show lower
basal testosterone levels (Abs et al., 2000; Finch, Roberts, Price, Hadlow, & Pullan,
2000; Malik, Khan, Jabbar, & Iqbal, 1992; Rasheed, & Tareen, 1995). In opioid-induced
hypogonadic men with chronic pain, those given exogenous testosterone reported a
significant improvement in their pain in several pain measurements as well as in sexual
functioning (Aloisi et al., 2011; Basaria et al., 2015). Furthermore, in a groundbreaking
study involving transgender individuals and chronic pain, females transitioning to males
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undergoing androgen replacement therapy reported a significant reduction in their
chronic pain (Aloisi et al., 2007). On the contrary, males transitioning to females taking
estrogen, or an anti-androgen reported an exacerbation of their chronic pain.
Experimental studies have also found a link between testosterone and pain. Choi
et al. (2006) found that in female subjects who had high levels of basal testosterone who
performed a pain task in their follicular stage of their menstrual cycle had greater
activation of the left precentral gyrus and reduced activation of right thalamus, providing
evidence that testosterone dampened pain in these females. Female oral contraception
users with low testosterone were discovered to have lower threshold for pain by reporting
pain at lower temperatures in a noxious thermal task than females with higher
testosterone, and that activation of the rostral ventromedial medulla was reduced (Choi et
al., 2006). Brain activation has also been found to differ in males as well. Males in a high
placebo condition (strongly led to believe that an analgesic would be effective) had
higher levels of testosterone, decreased pain, and stronger activation in the premotor
areas, ACC, and the prefrontal cortex (Choi et al., 2011). Another study examined
competitors in Kumdo, a Korean martial art, and found that pain was decreased after
competition. This was positively related to an increase in testosterone post competition
(Choi et al., 2013).
Based on the evidence from chronic pain studies and experimental studies, it is
evident that pain is influenced by the presence and level of testosterone. The male
androgen acts as an analgesic in humans to modulate pain expression in males. However,
there are limitations to these human studies. First, there are limited studies that have
examined the relationship between testosterone and pain in humans. No study has
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experimentally manipulated the participant’s testosterone levels to establish a causal link
between the actions of this hormone and pain. While increased testosterone does alter
chronic pain in opioid induced hypogonadic men and transgender males (Aloisi et al.,
2011; Aloisi et al., 2007; Basaria et al., 2015), it is not known if testosterone alters acute
pain in healthy individuals.
Testosterone Administration Methods
To better understand the relationship between testosterone and pain, it is vital to
establish causal relationships by administering testosterone to participants. However, it is
important that this is done safely and with minimal risk to the participants. Several
methods exist for administering testosterone and dosages vary within and between
methods.
Intramuscular injections. Studies examining men receiving intramuscular
injections of anabolic-steroids with dosages ranging from 40 mg to 600 mg found not to
moderate changes in behaviors (Bhasin et al., 1996; Su et al., 1993; Yates, Perry,
MacIndoe, Holman, & Ellingrod, 1999). In females who received 40 mg of testosterone
through intramuscular injections, anger proneness increased after 3 months, but overall
aggressive behaviors did not (van Goozen, Frijda, & van de Poll, 1995).
Topical application. Another method of administration is topical application.
Dosages for these studies also vary. In a study examining depression, men who received
100 mg of testosterone topically over several weeks reported less depression than men
that received a placebo (Pope, H. G., Cohane, G. H., Kanayama, G., & Hudson, J. I.
2003). Men who were given 150 mg of testosterone topically selected images of
themselves that were altered to appear more dominant. Finally, 50 mg of topically
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applied testosterone has been shown to increase prosocial behaviors (i.e., decreased
lying) in males (Wibral, Dohmen, Klingmüller, Weber, & Falk, 2012).
Sublingual administration of testosterone. A major concern when giving
exogenous testosterone to participants is safety. Exogenous testosterone is known to have
many detrimental side-effects (Kindlundh, Isacson, Berglund, & Nyberg, 1998;
Nieminen, Rämö, Vitasalo, Heikkilä, Karjalainen, Mäntysaar, & Heikkilä, 1996). In the
literature, sublingual administration using a 0.5 mg dosage has been used to safely
increase female participants’ testosterone while at the same time still being powerful
enough to alter behaviors. This method, first used by Tuiten et al. (2000), was found to
increase female participants’ testosterone by 10-fold after 15 minutes of administration.
Within 90 minutes after administration, the subjects returned to baseline levels of
testosterone. After 4 hours of administration, subjects reported increased vaginal
responsiveness, increased vaginal sensations, and sexual lust.
Because of the ease of administration, consistency in dosage, and relatively fast
induction of behavior change, sublingual administration has many advantages over other
methods. Sublingual administration in female has shown to reduce empathy (Hermans,
Putman, & van Honk, 2006; van Honk et al., 2013), impair moral judgment (Montoya et
al., 2013), reduce unconscious fear (van Honk, Peper, & Schutter, 2005), and alter stress
response (Hermans et al., 2007). These studies have helped establish a causal link
between testosterone and several behaviors. Based on the results reported in the literature,
it can be argued that the induction method produces prototypical “male-like” behaviors in
females. As such it is important to examine pain behaviors using this method of
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testosterone induction to see how females react to pain after elevation in their
testosterone level.
Current Study
There are many unanswered questions when concerning testosterone and pain.
The current study attempted to answer some of those questions by exploring a causal link
between testosterone and pain by experimentally manipulating participants’ testosterone
level. The study has the potential to illuminate the role of testosterone in pain and could
be a stepping stone in a line of research that could not only treat pain, but also aid in the
diagnosis of pain conditions in males and females. This is especially relevant considering
the opioid epidemic in the United States (Manchikanti et al., 2012). It is important to
note, to our knowledge this is the 1 st study that has directly manipulated testosterone in
humans while examining pain perception. The main hypothesis of this study is that when
a female participant is given the testosterone intervention, they will exhibit better pain
tolerance than a participant who receives a placebo.
Due to the exploratory nature of this project, several sub-hypotheses were
proposed. As discussed above, testosterone influences a range of human behaviors, some
of which have not been addressed using experimental manipulation. In keeping with the
theme of the main hypothesis, several of these sub-hypotheses are concerning overall
health. Sub-hypothesis 1: Sex differences in mortality indicate that women live longer
than men (Owens, 2002), but men overwhelmingly report their health to be better than
females and less instances of illnesses (Olsen & Dahl, 2007). Since testosterone alters
psychosocial behavior, it is possible that testosterone is altering self-perceived health in
men. In this study, we examined whether administration of testosterone in females would
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also alter self-perceived health. Sub-Hypotheses 2: Similarly, disgust sensitivity varies by
sex, in general, females are more sensitive to disgust stimuli than males (Davey, 1994;
Haidt, McCauley, & Rozin, 1994; Schienle, Stark, Walter, & Vaitl, 2003). However,
evidence indicates that females are more sensitive to disgusting stimuli with regards to
sexuality (Tybur, Bryan, Lieberman, & Hooper, 2011; Tybur, Lieberman, &
Griskevicius, 2009). Again, it was hypothesized that testosterone might be influencing
the perception of disgust, which was explored in this study. Sub-hypothesis 3: Body
image is another trait that varies between the sexes with males perceiving themselves to
be more attractive than females (Feingold & Mazzella, 1998). Body dissatisfaction and
lower self-esteem have been associated with one another in females, but in males, body
dissatisfaction does not seem to influence self-esteem (Furnham, Badmin, Sneade, 2002).
Perception of body image could also be influenced by testosterone which was explored in
this study. Sub-hypothesis 4: Sex differences have been reported in responses to sexual
stimuli with males being more concerned with regards to the actor they were observing
while women were more interested in the context of the sexual stimuli (see Rupp &
Wallen, 2008 for a review). Testosterone could be differentially influencing the interest
in specific sexual stimuli which was investigated in this study.
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Chapter 2: Methods
Participant Characteristics
A convenience sample was recruited from the University of New Mexico (UNM)
Psychology SONA system. The SONA system consists of subject pool drawn from
Introduction to Psychology classes at UNM. Twenty healthy female participants (M Age =
18.7 [0.92]) took part in this study. Of the 20 participants in this study, 17 reported to be
exclusively heterosexual, 2 to be bisexual, and 1 to be mostly homosexual. These
participants were not taking any form of hormonal contraceptive and therefore were in
their natural menstrual cycle. All females were targeted in their luteal phase of their
cycle, which was determined from their last reported menstruation using a forward
counting method and only women who reported having a regular menstrual cycle were
eligible. Typically, ovulation is thought to occur between the 10th and the 14th day of the
menstrual and therefore, we generally aimed for the 17th day of their cycle. All
participants were asked to inform the experimenter if menstruation had occurred before
the start of their first session. If menstruation had occurred, participants were rescheduled for another date. Exclusion criteria included individuals with a history of
chronic pain, and/or peripheral nerve damage. Participants were excluded if they were
taking blood thinners, corticosteroids, oxyphenbutazone, triamcinolone or any other
prescription or supplement drugs that might alter their baseline testosterone level.
Participants were not allowed to participate if they reported not feeling well. Pregnant
female subjects were also excluded from this study using urine pregnancy tests.
Sampling Procedures
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The study consisted of 2 experimental sessions that were approximately 5 hours
per session. Participants who met the initial inclusionary criteria were invited to the lab
for a pre-lab session. During this session participants were informed of the risks and
benefits of their participation in the study and to verify their time commitment. Once the
prospective participants had read and stated they understood what was required of them,
they were allowed to sign the consent form and schedule their first lab visit.
On their first lab visit, participants were pre-screened for pregnancy, tree nut
allergies, and any self-reported use of drugs (e.g., insulin, blood-thinners, corticosteroids,
oxyphenbutazone, triamcinolone) that may alter their testosterone level. For both
sessions, female participants were continually screened for pregnancy. During the course
of the experiment, no female subjects tested positive for pregnancy. All participants were
asked about any new medication used before the start of each session. Since exercise,
sexual behaviors, and competitive activities may increase testosterone, all participants
were instructed to avoid these activities on the day of their participation. Health status of
all female participants was also carefully monitored to ensure they were all physically
capable to participant in this study.
Participants were randomly assigned to either a placebo or a testosterone group
before arrival. The experimenters were blinded to this assignment. Randomization of the
placebo and experimental drugs were controlled by research pharmacist. All participants
filled out a short survey for basic demographic information at the first experimental
session after completion of the consent form.
Participants provided an initial saliva sample to establish their baseline
testosterone level. Once they had given this sample, participants were either given the

18

drug intervention or a placebo. Upon being given the intervention, participants completed
the first Balloon Analogue Risk Task (BART). They then provided the last saliva sample
15 minutes following the intervention. Participants remained in the lab for the duration of
this 5-hour session. They were allowed to watch Netflix and listen to music as they
waited. However, the content they viewed or listened to was limited to G or PG ratings in
order to avoid potential fluctuations in their testosterone level. Participants were
instructed to turn their cell phones off to ensure that their mood was not significantly
altered. At the 4-hour mark, participants completed the pain task, questionnaires, the
Three Domain Disgust Videos (TDDV) Disgust task, and the BART, respectively. Once
this was completed, subjects were paid based on the money they earned during the
BART. Each participant was also paid $5 for each session. The sessions were 3 days
apart between the experimental sessions to ensure participants remain in their luteal
phase. Participants were reminded about their informed consent before the start of their
second session to ensure they understood their continued rights as research participants.
In addition to being paid for their participation, participants were also awarded 3 research
credits for each session for a total of 6 credits.
Pain Tasks
The ischemic discomfort task uses a sphygmomanometer (blood pressure cuff)
placed 5 cm below the participant’s elbow. Participants were instructed to raise their arm
vertically in the air and hold in place for 1 minute to desanguinate the limb. The cuff was
then inflated to 200 mmHg over the course of 20 seconds. The subjects were asked to
lower their arm and perform handgrip exercise for a 30 second period. This procedure
was previously found to be safe and effective means in producing pain (Johnson &
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Tabasam, 2003; Ring et al., 2007). Participants were then asked to report when they first
felt discomfort, first felt pain, and when they wanted to stop the task. This “stop time”
was used as an indicator of pain tolerance. The more tolerant they were of pain, the later
their stop time. Participants also reported their pain using a visual analogue scale (VAS)
every 30 seconds. Participants were told they could discontinue the experiment at any
time and were not allowed to exceed 6 minutes in the pain task. If a participant made it to
6-minute mark, the experimental task was automatically discontinued.
Behavioral Tasks
Balloon Analogue Risk Task (BART). The BART is a computerized measure of
risk-taking behavior (Lejuez et al., 2002). In this task, participants are asked to inflate 60
virtual balloons using a pump. Each pump earns the participant 5 cents from which the
participant can either choose to collect the money at any time or continue to pump in
order to gain more money but at the risk of popping the balloon and losing any money
earned. At the end of the task, participants collect the money earned in their bank.
However, if the balloon “pops” as a result of inflating it too much, the participant does
not earn any money from that balloon and a new balloon appears. The “explosion point”
varied depending on the type of balloon the participant viewed. An adjusted average
number of pumps was computed for each session completed. This adjusted average
consisted of the average pumps of each trial in which the balloon did not explode.
Three Domain Disgust Videos (TDDV). The TDDV Task is comprised of 20
short videos that are based on the Three Domain Disgust Scale (Del Giudice,
unpublished). Like the Three Domain Disgust Scale (Tybur, Lieberman, & Griskevicius,
2009), this task is comprised of three domains of disgust: pathogen (Testosterone Group
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 = .69, Placebo Group  = .91), moral (Testosterone Group  = .58, Placebo Group  =
.85), and sexual (Testosterone Group  = .91, Placebo Group  = .89) . The participants
viewed 5 short videos in each domain in addition to 5 neutral videos. Using a 9-point
Likert Scale, participants rated the videos from “not at All Disgusting” to “extremely
disgusting.” The TDDV Task was found to have a similar factor structure as the Three
Domain Disgust Scale, and the pattern of sex difference was also similar (i.e., females
were more sensitive to sexual disgust stimuli than males).
Self-Report Questionnaires
SF-36 Health Survey. The SF-36 Health Survey is a 36-item survey, which is
commonly used to assess self-reported physical and mental health in the medical field
(Appendix A: Turner-Bowker, DeRosa, & Ware Jr., 2008). There are two broad domain
scale measures that assess physical and mental health. The survey also has 8 sub-scales
which include: physical functioning (PF), role-physical (RP), bodily pain (BP), general
health (GH), vitality (VT), social functioning (SF), role-emotional (RE), and mental
health (MH).
Buss-Perry Aggression Questionnaire-Short Form. The original Buss-Perry
Aggression Questionnaire (Appendix A: Buss & Perry, 1992) was a 29-item
measurement of aggression with 4 subscales: physical (Testosterone Group  = .87,
Placebo Group  = .70) , verbal (Testosterone Group  = .50, Placebo Group  = .21),
anger (Testosterone Group  = .42, Placebo Group  = .64), hostility (Testosterone
Group  = .60, Placebo Group  = .45), and total aggression (Testosterone Group  =
.91, Placebo Group  = .87). For the purposes of this study, a refined 4 factor short-form
(i.e., 12 items) was used (Bryant & Smith, 2001). This new refined questionnaire was
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generalizable to subjects in three different countries and was equivalent for both males
and females.
Domain-Specific Risk-Attitude Scale. To measure risk taking behaviors we used
the domain-specific risk-attitude scale developed by Weber, Blais, and Betz (2002). This
scale assesses 5 domains of risk taking behaviors, which include: financial (Testosterone
Group  = .69, Placebo Group  = .69) , health/safety (Testosterone Group  = .59,
Placebo Group  = .61), recreational (Testosterone Group  = .75, Placebo Group  =
.79), ethical (Testosterone Group  = .90, Placebo Group  = .84), social risks
(Testosterone Group  = .74, Placebo Group  = .64), and total aggression (Testosterone
Group  = .88, Placebo Group  = .84). The scale contains 50 statements pertaining to
the different risk-taking domains in which the subjects use a Likert scale to state how
likely or how unlikely they were to perform the activity (Appendix A).
Body-Esteem Scale. The Body-Esteem Scale is a 35-item survey that assesses
how participants perceive their own body (Appendix A: Franzoi & Shields, 1984). The
scale consists of 3 sub-scales: weight concern (Testosterone Group  = .89, Placebo
Group  = .88), physical condition (Testosterone Group  = .86, Placebo Group  = .86),
and sexual attractiveness (Testosterone Group  = .76, Placebo Group  = .76). This
survey has been used consistently in the literature over the last 30 years, and has only
been recently revised (Frost, Franzoi, Oswald, & Shields, 2018).
Self-Perceived Mating Success Scale. This is a 10-item survey, which assesses
the participants’ perceived mating success using a 7-point Likert scale (Appendix A:
Landolt, Lalumière, and Quinsey, 1995). An example of one of the questions is “I am
able to attract individuals I find desirable as relationship partners.” Two of the items are
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reverse scored and all scores added together to form a composite score (Testosterone
Group  = .78, Placebo Group  = .77) called “mate value.”
Three Domain Disgust Scale. The Three Domain Disgust Scale (Appendix A) is
a 21-item measurement consisting of three sub-scales: moral (Testosterone Group  =
.79, Placebo Group  = .84), sexual (Testosterone Group  = .89, Placebo Group  =
.89), and pathogen (Testosterone Group  = .68, Placebo Group  = .75: Tybur,
Lieberman, & Griskevicius, 2009). This scale used a 7-point Likert scale in which the
participants were asked to rate items as “Not Disgusting at All” to “Extremely
Disgusting.” An example of an item would be “Hearing two strangers have sex.” In
development, a consistent sex difference was found using this scale in which female
participants were more sensitive to sexual disgust than males.
Interest in Visual Sexual Stimuli. This scale is a 10-item measurement that uses
a 7-point Likert scale that assesses interest in sexual stimuli (Appendix A: Bailey, Gaulin,
Agyei, & Gladue, 1994). An example of an item is, “If I met someone I found very
attractive right now, I would fantasize about what they would look like without clothes
on.” Items 5 and 9 were reverse scored and all items were summed together to form a
score on this scale referred to as sexual attitudes (Testosterone Group  = .86, Placebo
Group  = .91) in the analysis.
Hormonal Assessment
Each subject was given a saliva oral swab for saliva collection. Participants were
instructed to lightly chew on the cotton swab for approximately 1 minute then instructed
to place the swab in a test tube where it will be stored 4 C. Three hormones were
measured from the participant’s saliva: testosterone, estradiol, and progesterone. All
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saliva assays were processed at the Hominoid Reproductive Ecology Laboratory located
on UNM Main Campus. Saliva swab tubes were centrifuged for 15 minuets at 4 C. Once
saliva samples were purified, Salimetrics enzyme-linked immunosorbent assay (ELISA)
diagnostic kit was used to extract testosterone, estradiol, and progesterone levels. For
testosterone, interassay coefficients of variation (CVs) were 11.67% for a high control,
a0.96 % for a low control, and the intraassay CV was 4.65%. For estradiol, interassay
CVs were 2.64% for a high control, 3.35 % for a low control, and the intraassay CV was
1.95%. For progesterone, interassay CVs were 0.98% for a high control, 35.25 % for a
low control, and the intraassay CV was 3.89 %. Testosterone measurement using salivary
sample has been found to be a reliable indicator of assessing hormonal level of
individuals and has been used for diagnoses of endocrine dysfunction in both males and
females (Cardoso, Contreras, Tumilasci, Elbert, Aguirre, Aquilano, & Arregger, 2011;
Karrer-Voegeli, Rey, Reymond, Meuwly, Gaillard, & Gomez, 2009; Morely, Perry,
Dollbaum, & Kells, 2006; Shirtcliff, Granger, & Likos, 2002).
Testosterone Administration
The Testosterone and placebo were dispensed in oil-based sublingual product
prepared by the UNM Investigational Drug Service Pharmacy (see Appendix B for more
details). It was thought that using the 0.5 mg dosage for this study would reduce the risk
of any potential adverse effects as these methods have also been safely used in other
research designs. A medical doctor on staff prescribed the testosterone. Either the
experimental testosterone or a placebo was prepared on the day of the experimental
session which was picked up by a member of the research team. The experimenter and
participants were blinded on whether they received testosterone or placebo. Prior studies
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have found that 0.5 mg of testosterone is a safe and effective means to manipulate
testosterone level in females and produce behavioral effects (Herman, Putman & van
Honk; 2006; Hermans, Ramsey, & van Honk, 2008; Montoya et al., 2013; Tuiten, et al.,
2000; van Honk et al., 2004). From the pilot study (Strenth, Kruger, Thompson, Vigil,
Reeves, in preparation) and previous studies, we found that females quickly metabolize
testosterone after administration and many returned to their baseline level by 3 hours and
30 minutes after the administration.
Statistical Analysis
Linear mixed effect models were used for the analysis of testosterone, estradiol,
and progesterone outcome variables in R version 3.4.3 (R Core Team, 2017) using the
nlme package (Pinheiro, Bates, debRoy, Sarkar, & R Development Core Team, 2013). A
two-level random intercept model was fit using 80 observations. The model included the
main effects of time-point (pre vs. post), the intervention (placebo and testosterone), and
the time * intervention interaction at the first level. The first level was nested in the
participants, which served as the second level. The testosterone variable was non-normal
and was log transformed to correct for this.
Several one-way repeated measures analysis of variance (ANOVAs) were
conducted to examine the within-subject effect of the drug intervention on the remainder
of the outcome variables. These analyses were carried out using SPSS Version. 25. The
Sphericity assumption was met for all analyses.
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Chapter 3: Results
Testosterone, Estrogen, and Progesterone
Table 1 displays the two-level multilevel model summary table for the
testosterone dependent variable. There was a significant main effect of time ( = 0.18, SE
= 0.05, p = 0.002) and a significant interaction between time and the intervention (
=1.16, SE = 0.07., p < 0.001). A test of the simple effects found a significant effect for
the testosterone intervention when moving from pre to post time-points (MD = -1.34, t[57]
= -25.38, p < 0.001, See Figure 1). Table 2 displays the two-level multilevel mode
summary table for the estradiol dependent variable. A significant interaction between
time and the intervention variable was found when predicting estradiol ( = 1.08, SE =
0.25, p < 0.001). A test of the simple effects found a significant effect for the testosterone
intervention when moving from pre to post time-points for estradiol (MD = -0.90, t[57] = 5.02, p < 0.001, See Figure 2). Finally, Table 3 displays the two-level multilevel model
summary table for the progesterone dependent variable. A significant interaction between
time and intervention was found ( =453.02, SE = 97.33, p < 0.001). Finally, A test of the
simple slopes found a significant effect for the testosterone intervention when moving
from pre to post time-points for progesterone (MD = -423.64, t[57] = -6.16, p < 0.001, See
Figure 3)
Pain
Three one-way repeated measure ANOVAs were carried out comparing the
placebo with the testosterone intervention on the three pain variables: discomfort, pain,
and stop. Table 4 displays the means, standard deviations, and within-subject test of the
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pain variables. The placebo group did not differ from the testosterone group on any of the
pain variables (p > 0.05).
Health
Eight Three one-way repeated measure ANOVAs were carried out comparing the
placebo with the testosterone intervention on the eight health variables: PH, RP, BP, GH,
VT, SF, RE, and MH. Table 5 displays the means, standard deviations, and withinsubject test of the health variables. There was a significant effect of drug intervention on
PH (F [1, 19] = 4.74, p = 0.04, 2 = 0.20). Female participants who received the
testosterone intervention reported higher PH than females who received the placebo. The
placebo group did not differ from the testosterone group on any of the remaining health
variables (p > 0.05).
Aggression
Five one-way repeated measure ANOVAs were carried out comparing the
placebo with the testosterone intervention on the five aggression variables: hostility,
anger, verbal, physical, and total aggression. Table 6 displays the means, standard
deviations, and within-subject test of the aggression variables. The placebo group did not
differ from the testosterone group on any of the aggression variables (p > 0.05).
Risk-Taking
Seven one-way repeated measure ANOVAs were carried out comparing the
placebo with the testosterone intervention on the five risk-taking variables: recreational,
health, ethical, financial, social, total risk and the BART. Table 7 displays the means,
standard deviations, and within-subject test of the risk-taking variables. There was a
significant effect of drug intervention on the BART (F (1, 19) = 5.11, p = 0.03, 2 =
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0.21). Female participants who received the testosterone intervention had a higher
adjusted average number of pumps when inflating the balloons than females who
received the placebo. However, the placebo group did not differ from the testosterone
group on any of the remaining health variables (p > 0.05).
Body Self-Esteem
Three one-way repeated measure ANOVAs were carried out comparing the
placebo with the testosterone intervention on the three body self-esteem variables: PC,
WC, and SA. Table 8 displays the means, standard deviations, and within-subject test of
the body self-esteem variables. The placebo group did not differ from the testosterone
group on any of the body self-esteem variables (p > 0.05).
Mate Value and Sexual Attitudes
Two one-way repeated measure ANOVAs were carried out comparing the
placebo with the testosterone intervention on the mate value and sexual attitudes
variables. Table 9 displays the means, standard deviations, and within-subject test of the
body self-esteem variables. A difference between the placebo and testosterone group
approached significance for the mate value variable (F [1, 19] = 3.83, p = 0.06, 2 = 0.17)
with females receiving the testosterone intervention reporting higher mate value. The
placebo group did not differ from the testosterone group on the sexual attitudes scale (p >
0.05).
Disgust
Six one-way repeated measure ANOVAs were carried out comparing the placebo
with the testosterone intervention on the six disgust variables: moral, sexual, pathogen,
TDDV moral, TDDV sexual, and TDDV disgust. Table 10 displays the means, standard
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deviations, and within-subject test of the disgust variables. The placebo group did not
differ from the testosterone group on any of the disgust variables (p > 0.05).
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Chapter 4: Discussion
The current study found additional support for the alteration of endogenous
testosterone in female participants by sublingual administration of exogenous
testosterone. Additionally, this study has provided evidence that this method of
testosterone administration alters the sex hormones estradiol and progesterone. In
examining pain variables, our intervention did not alter times in which the participants
first reported pain, first reported discomfort, or when they wanted to stop the pain task.
PF was altered due to the intervention with participants reporting higher physical
functioning than females who received placebo. The placebo and the testosterone group
also differed in the BART with female participants given the testosterone intervention
increased their pumps for each balloon indicating higher risk-taking behavior. A
difference between the placebo and testosterone intervention approached significance
when examining the mate value variables. However, all other variables: aggression, risktaking, body self-esteem, sexual attitudes, and disgust were non-significant.
Testosterone, Estradiol, and Progesterone
Testosterone is readily converted into estradiol by both males and females
whether the source is endogenous or exogenous (Campfield, Saul, & Swerdloff, 1982;
Gibori & Kraicer, 1973; Hillier & Ross, 1979; Longcope, Kato, & Horton, 1969; Sokol,
Palacios). This is not surprising since testosterone is a precursor to estradiol and is
converted by enzyme aromatase (Ishikawa, Glidewell-Kenney, & Jameson, 2006).
Therefore, with this type of administration, one would expect that part of the exogenous
testosterone would be converted into estradiol.
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It is unclear as to why progesterone was also significantly increased in females.
Previous studies that examined the relationship between exogenous testosterone and
progesterone have found that the male sex hormone does not influence the production of
progesterone (Hillier & Ross, 1979; Richardson & Masson, 1981). However, little has
been published on this relationship. Unlike estradiol, progesterone is produced early on in
the steroidogenesis pathways, which takes cholesterol and converts into the many steroid
hormones found in the body (see Miller & Auchus, 2011 for a review). Meaning that
neither hormone should influence the other. It is possible that the surge in testosterone
due to the intervention disrupted the normal regulatory pathway that controls
steroidogenesis in the hypothalamic-pituitary-gonadal (HPG) axis. As a result, this leads
to not only increase in testosterone and estradiol but also augmentation of other hormones
as well.
Another possible explanation for elevated levels of estradiol and progesterone
could be due to the actions of sex hormone binding globulin (SHBG). SHGB is a protein
that binds to the majority of circulating androgens and estrogens and reduces their
bioavailability (Anderson, 1974). Concentrations of SHBG are positively associated with
concentrations of estrogen, and thus are higher in adult females versus males (Goto et al.,
2014; Edlefsen et al., 2010). This protein has a higher affinity to bind to androgens than
to other sex hormones. Therefore, it is possible that female participants may have
elevated SHBG in their systems such that exogenous testosterone administered would be
bound by the SHGB making it appear that other hormones such as estradiol and
progesterone are higher in concentration. Future research should consider measuring
SHGB in relation to this method of testosterone administration.
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Time course effects were not explored in this study, so it is unknown whether this
increase in estradiol, and progesterone was temporary, relative to the increase in
testosterone or whether these increases were similar. Like testosterone, it is possible that
elevations in estradiol and progesterone might affect behavior at a much later time.
Whereas the behavioral effects of testosterone might manifest around 4 hours, the
elevations in estradiol and progesterone might influence behavior before or after 4 hours.
This study showed an initial increase in estradiol and progesterone, however, as
testosterone is converted to estradiol, it could be possible to see another rise in estradiol
and progesterone. Future testosterone administration studies should explore the
relationship between these three hormones over time. However, the increases in estradiol
and progesterone does call into question whether the effects found in previous studies are
the result of testosterone alone or whether it is actually contribution of all three
hormones.
How these hormones interact with each other when elevated is not known. It was
previously noted that estradiol tends to exacerbate pain when elevated. Testosterone
might dampen pain, but this may be relative to the level of estradiol. The fact that pain
and several other behaviors were unaffected by the intervention may be the result of the
individual effects of each hormone canceling each other out. Therefore, estradiol and
progesterone might need to be relatively low in relationship to testosterone for pain to be
dampened.
Pain
Prior research examining opioid-induced hypogonadism in men, and transgender
men found that testosterone alleviated chronic pain symptoms in these individuals (Aloisi
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et al., 2011; Aloisi et al., 2007; Basaria et al., 2015). The current study did not find that
the testosterone intervention altered pain tolerance. However, testosterone should not be
ruled out for altering pain perception. The aforementioned studies administered
testosterone multiple times and at a much higher dose whereas we used a very small dose
in comparison. For pain to be altered, organizational changes to the body as a result of
high dosages of testosterone may be required. Future research on this topic should
explore the relationship between the variations in dosages and the cumulative effect of
multiple doses.
The current study only used one type of pain task, and it is possible that
testosterone may alter specific domains of pain. For example, pregnant women have been
found to be more sensitive to heat pain than cold pain (Carvalho et al., 2006). The
ischemic pain task used in this study is thought to produce a deep muscular pain. This
type of pain might be a symptom of a more serious injury and may not be dampened by
testosterone. A more superficial pain (e.g. heat/cold pain) may be dampened more by the
effects of testosterone than a muscular pain.
This study found no effect of exogenous testosterone on pain in the short-term,
however, this study does contribute to the scientific literature by providing more evidence
on the use of testosterone as an aid to pain. When considering treatment modalities for
pain, an acute administration of testosterone might not make a difference in pain
perception in the short-term, but it is possible that at higher doses over the course of time
could be used in conjunction with opioids to either reduce pain or reduce the use of
opioids in individuals suffering from chronic pain or extreme trauma. More research is
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needed, and the positive effects of testosterone need to be weighed against its sideeffects. Yet, it still might be possible to use this hormone in the management of pain.
Health
Men report better health and less diseases than women even though male’s
mortality is higher than females (Olsen & Dahl, 2007; Owens, 2002). Women given
testosterone reported greater physical functioning (e.g. climbing stairs, bending, kneeling,
and walking moderate distances) than women who received placebo. Testosterone,
therefore, maybe altering the perceptions of the individual; in someone who has high
testosterone believes they are more capable of physical tasks that would normally be
painful. There were no other significant differences between the placebo and testosterone
interventions when addressing the other sub-scales of the SF-36 Health Survey. A study
examining the effect of exogenous testosterone in older men and the SF-36 Health
Survey found that both the placebo group and the testosterone groups had declining
perceived physical and mental health after a 12-month period (Kenny, Bellantonio,
Gruman, Acosta, & Prestwood, 2002). However, decline in perceived health might be
due more to the complications of old age. A study on hypogonadal men given
testosterone, found that testosterone supplementation improved energy, good feelings,
and friendliness (Wang et al., 1996). More research is needed to elucidate the relationship
between perceived health and testosterone.
Considering possible treatments in relation to the findings of this study, it might
be feasible to use testosterone to treat pain catastrophizing. Pain catastrophizing consists
of repeated thoughts of worry that tend to exacerbate pain which can be debilitating, and
these thoughts are common among those who suffer from chronic pain (Keogh &
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Asmundson, 2004; Sullivan et al., 2001). In this study, testosterone increased perceived
physical functioning in normal female participants. Testosterone could be used as a
treatment for individuals suffering from chronic pain to treat pain catastrophizing for
chronic pain patients, which may motivate these patients to engage in behaviors or
activities that they previously thought may cause pain. As of yet, pain catastrophizing has
not been examined using testosterone.
Risk-Taking
When female participants received testosterone, their average pumps for the
BART increased significantly, meaning participants engaged in riskier behaviors in order
to attain larger monetary rewards in the BART. This finding confirms previous research
showing that high endogenous levels of testosterone are associated with increased risktaking behaviors (Ronay & Hippel, 2010; Stanton, Liening, & Schultheiss, 2011; van
Honk Schutter, Hermans, Tuiten, & Koppeschaar, 2004; Vermeersch, T’Sjoen, Kaufman,
& Vincke, 2008). This is the first study to show that exogenous testosterone alters risktaking when participants are using the BART.
However, despite the significant findings with the BART, the risk-taking
subscales for the Domain-Specific Risk-Attitude Scale were all non-significant. It is
possible that this behavior scale, which used a 6-point Likert-scale, was not sensitive
enough to detect the changes in behavior caused by the testosterone intervention. Several
flaws have been pointed out concerning the use of self-report measures: such as
participants lacking the ability to accurately self-report and the tendency for participants
to respond in ways perceived as socially acceptable (John & Robins, 1994; Paulhus,
1991). The BART, therefore, might have been a more reliable to assess risk-taking

35

behaviors than the Domain-Specific Risk-Attitude Scale. This is evident by the low
Cronbach’s alphas found for the sub-scales of this scale.
Aggression
None of the sub-scales to the Buss-Perry Aggression Questionnaire Short-Form
were altered due to the intervention. This is a surprising finding considering body of
research linking aggression with testosterone (see Archer, 2006 for a review). Again, this
questionnaire uses a 5-point Likert scale, and may not have been sensitive to detect
variations in aggression due to the testosterone intervention. Like with the DomainSpecific Risk-Attitude Scale, participants could have also been reluctant to self-report on
behaviors that are not socially acceptable.
Body Self-Esteem, Mate Value, and Sexual Attitudes
The current study did not find any significant differences between the placebo and
testosterone intervention for any of the measures of body self-esteem and sexual
attitudes. A difference between the placebo and testosterone intervention approached
significance for the mate value variable. Previous research on sexual motivations and
body image has suggested that for women, estradiol and progesterone play a more
significant role in these behaviors than testosterone (Carr-Nangle, Johnson, Bergeron, &
Nangle, 1994; Eisenbruch, Simmons, & Roney, 2015; Roney & Simmons, 2013).
Previous research has linked attractiveness with endogenous levels of estradiol and
progesterone (Jasienska, Ziomkiewicz, Ellison, Lipson, Thune, 2004), however, a large
study on attractiveness and hormones recently found no relationship between
attractiveness, progesterone, and estradiol (Jones et al., 2018). More research is needed to
confirm what role, if any, testosterone plays in sexual motivations and body image.
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Disgust
None of the disgust variables were influenced by the testosterone intervention.
Again, it is possible that estradiol and progesterone play a bigger role in disgust
sensitivity than testosterone. A study on pregnant women found women were more
sensitive to disgusting stimuli during the first trimester of pregnancy (Fessler, Eng, &
Navarrete, 2005). This could be an indication that estradiol and progesterone are
influencing perceptions of disgust. Future research should examine how these hormones
influencing disgust.
Limitations
The intervention proved to not be influential to many of the outcomes investigated
in this study. A reason for this might be due to the sample size. Many of the outcomes
investigated in this study have not been examined using this method administration or
dosage. Although the sample size used in this study is comparable to previously
published studies (Hermans, et al., 2006; van Honk et al., 2013), the effects under
investigation were probably smaller requiring a larger sample size in order to capture
them.
Thirty-five within-subject analyses were performed, and it is possible that
significant findings found for PF and BART are product of random chance rather than
actually being significant differences between the groups (Tukey, 1991). That being said,
the findings from this current study concerning these two variables should be considered
in light of this.
In the pain tasks, all of these experimental procedures were carried out by a male
experimenter. Previous research has shown that women report pain differently depending
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on the sex of the experimenter whether short or long exposure (Vigil & Coulombe, 2011;
Vigil et al., 2015; Vigil, Rowell, Alcock, Maestes, 2014;). It is possible that female
participants’ pain response was being influenced by the presence of the male
experimenter, which could have superseded the effect of the drug intervention.
Testosterone administration studies that examine pain should try in the future to have
mixed sex experimenters to see if the effect of the administration differs between the
sexes.
All female participants were examined during the luteal phase of their menstrual
cycle however, it is not known whether this method of administration varies across the
menstrual cycle. For example, a meta-analysis on menstrual cycle effects on pain found
women were more sensitive to pain during the luteal phase (Rilley III, Robinson, Wise, &
Price, 1999). It is possible that the females in this study were already “primed” to be
more sensitive to pain. The momentary flux in testosterone might have done little to
influence this menstrual cycle effect on pain. More research is needed to explore how
different phases of the menstrual cycle influence testosterone administration.
Several measures were used in this study and it is possible that some of those
measures were measuring trait behaviors while others were measuring state behaviors. A
personality trait can be defined as aspect of a person’s personality that does not change
and is consistently the same, whereas a state attribute is how that individual feels in that
moment (Watson & Pennebaker, 1989) The measures of aggression, body self-esteem,
risk-taking, and some of the measures of the SF-36 Health Survey may have been
capturing trait-like behaviors. This indicates that the administration of testosterone would
not have as much effect on altering these behaviors. The null effects found with these
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variables might be due to the fact that one would not expect these behaviors to vary due
to temporary variations in hormonal levels. The measures of interest in sexual stimuli,
disgust, pain, and the BART, on the other hand, might be more appropriate to use in this
investigation since it could be argued that these are more “state-like” behaviors and are
more susceptible to variations in testosterone.
It is unknown whether a ceiling effect or floor effect exists with this type of
administration. It is possible that for some of the participants that the sudden increase in
testosterone was not as effective for some as it was for others. Testosterone, when
increased may not continue to alter behaviors past a certain point. There are no reported
ceiling effects or floor effects for this method of administration, but nevertheless, more
research is needed to explore the limits of this method.
Conclusions
The sublingual administration of testosterone altered not only endogenous levels
of testosterone, but also that of estradiol and progesterone. In light of these findings,
future administration studies should consider whether testosterone alone is influencing
behavior or whether it is a combination of all three hormones. Pain was not influenced by
exogenous testosterone, but it is possible that a small single dosage is not powerful
enough to alter pain in females. More research is needed to explore whether larger
dosages are required to alter pain. The findings with the PF variable provides further
evidence that testosterone may be altering one’s perceived health. Additional support is
also provided showing that testosterone alters risk-taking behaviors. While most of the
effects explored in this study were none significant, more research is needed using this
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method of administration to capture the effects of aggression, body self-esteem, sexual
attitudes, and disgust.
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Figure 1.
Bar Means of Log Transformed Testosterone by Time and Intervention

Note. Testosterone is log transformed in this graph. Error bars are 95% confidence intervals.
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Figure 2.
Bar Means of Estradiol by Time and Intervention

Note. Error bars are 95% confidence intervals.
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Figure 3.
Bar Means of Progesterone by Time and Intervention

Note. Error bars are 95% confidence intervals.
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Table 1
Multilevel Model Summary Table: Testosterone (Log)
Dependent Variable: Coefficient t test
p value
R2GLMM R2GLMC
Log
Bayesian
Testosterone (Log)
(SE)
Likelihood
Inf. Crit.
Intercept
5.29 (0.04)
105.88 < 0.001***
0.876
0.931
17.58
-8.87
Time
0.17 (0.05)
3.32
0.001***
Intervention
0.06 (0.05)
1.13
0.260
Time*Intervention
1.16 (0.07)
15.60
< 0.001***
Note. The testosterone outcome variable was log transformed for this analysis. The Time variable is a dummy
coded variable where pre-administration is equal to zero and post-administration is equal to one. R2GLMM is the
predicted variance for the fixed effects and R2GLMC is the predicted variance for the fixed effects and the random
effects. For mixed-models, R2GLMM and R2GLMC are the equivalent to R2 reported in linear models
(Nakagawa & Schielzeth, 2013). The Log Likelihood and the Bayesian Information Criterion variables are used
for model fit comparisons.
*p < 0.05; **p < 0.01; ***p < 0.001
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Table 2
Multilevel Model Summary Table: Estradiol
Dependent
Coefficient
t test
p value
R2GLMM R2GLMC
Log
Bayesian
Variable: Estradiol
(SE)
Likelihood
Inf. Crit.
Intercept
4.27 (0.20)
20.44 < 0.001*** 0.194
0.703
-86.82
199.93
Time
-0.18 (0.18) -1.00
0.320
Intervention
0.06 (0.18)
0.35
0.724
Time*Intervention
1.08 (0.25)
4.26
< 0.001***
Note. The Time variable is a dummy coded variable where pre-administration is equal to zero and
post-administration is equal to one. R2GLMM is the predicted variance for the fixed effects and R2GLMC is the predicted
variance for the fixed effects and the random effects. For mixed-models, R2GLMM and R2GLMC are the equivalent to
R2 reported in linear models (Nakagawa & Schielzeth, 2013). The Log Likelihood and the Bayesian Information
Criterion variables are used for model fit comparisons.
*p < 0.05; **p < 0.01; ***p < 0.001
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Table 3
Multilevel Model Summary Table: Progesterone
Dependent Variable: Coefficient t test
p value
R2GLMM R2GLMC
Log
Bayesian
Progesterone
(SE)
Likelihood
Inf. Crit.
Intercept
744.09 (83.60) 8.90 < 0.001*** 0.271
0.785
-7.99
42.28
Time
-29.38 (68.83) -0.43
0.67
Intervention
97.87 (68.83)
1.42
0.16
Time*Intervention 453.02 (97.33) 4.65 < 0.001***
Note. The Time variable is a dummy coded variable where pre-administration is equal to zero and
post-administration is equal to one. R2GLMM is the predicted variance for the fixed effects and R2GLMC is the predicted
variance for the fixed effects and the random effects. For mixed-models, R2GLMM and R2GLMC are the equivalent to
R2 reported in linear models (Nakagawa & Schielzeth, 2013). The Log Likelihood and the Bayesian Information
Criterion variables are used for model fit comparisons.
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Table 4
Descriptive Statistics and Within-Subjects Main Effects for Pain Variables
Descriptive Statistics
MP
SDP
MT
SDT

Within-Subjects Effects
F
df
p2
value

Outcome:
Placebo vs.
Treatment
Discomfort
48.86 46.31 43.38 28.83 0.310 (1,17)
0.59
0.01
Pain
92.84 42.16 88.25 45.45 0.365 (1,16)
0.55
0.02
Stop
224.93 94.08 224.21 91.14 0.005 (1,19)
0.95
0.00
Note. MP = Mean of the placebo group. MT = Mean of the testosterone group. SDP =
Standard deviation of the placebo group. SDT = Standard deviation of the testosterone
group. 2 = partial eta-squared. *p < 0.05; **p < 0.01; ***p < 0.001
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Table 5
Descriptive Statistics and Within-Subjects Main Effects for SF-36 Health Survey
Sub-Scale Variables
Descriptive Statistics
Within-Subjects Effects
Outcome:
MP
SDP
MT
SDT
F
df
p2
Placebo vs.
value
Treatment
PF
88.24 22.08 90.25 19.50
4.74
(1,19)
0.04*
0.20
RP
90.00 16.27 88.13 20.17
0.53
(1,19)
0.47
0.03
BP
77.80 24.55 82.90 18.49
0.91
(1,19)
0.35
0.05
GH
76.15 21.60 78.65 20.78
2.52
(1,19)
0.13
0.12
VT
64.69 14.80 63.44 19.05
0.35
(1,19)
0.56
0.02
SF
83.13 25.09 88.13 16.95
1.15
(1,19)
0.30
0.06
RE
84.17 19.48 83.33 20.23
0.11
(1,19)
0.74
0.006
MH
78.25 14.44 80.00 13.86
1.35
(1,19)
0.26
0.07
Note. PF = Physical Functioning. RP = Role Physical. BP = Bodily Pain. GH = General
Health. VT = Vitality. SF = Social Functioning. Role-Emotional = RE. MH = Mental
Health. MP = Mean of the placebo group. MT = Mean of the testosterone group. SDP =
Standard deviation of the placebo group. SDT = Standard deviation of the testosterone
group. 2 = partial eta-squared.
*p < 0.05; **p < 0.01; ***p < 0.001
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Table 6
Descriptive Statistics and Within-Subjects Main Effects for Buss-Perry Aggression
Short-Form Sub-Scale Variables
Descriptive Statistics
Within-Subjects Effects
Outcome:
MP
SDP
MT
SDT
F
df
p-value 2
Placebo vs.
Treatment
Hostility
5.85
2.13
5.55
2.35
0.46 (1,19)
0.51
0.02
Anger
4.80
2.14
4.45
2.01
1.21 (1,19)
0.29
0.06
Verbal
5.65
2.28
5.20
2.26
1.57 (1,19)
0.23
0.08
Physical
7.70
3.20
7.30
3.83
0.41 (1,19)
0.53
0.02
Total
24.00 8.72 22.50
9.37
1.13 (1,19)
0.30
0.06
Aggression
Note. MP = Mean of the placebo group. MT = Mean of the testosterone group. SDP =
Standard deviation of the placebo group. SDT = Standard deviation of the testosterone
group. 2 = partial eta-squared.
*p < 0.05; **p < 0.01; ***p < 0.001
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Table 7
Descriptive Statistics and Within-Subjects Main Effects for Risk-Taking Variables
Descriptive Statistics
Within-Subjects Effects
Outcome:
MP
SDP
MT
SDT
F
df
p2
Placebo vs.
value
Treatment
Recreational
31.40 7.32
31.80
6.43
0.13 (1,19)
0.72 0.007
Health
20.10 5.12
20.15
5.17
0.003 (1,19)
0.95
0.00
Ethical
17.10 5.60
18.05
8.40
0.64 (1,19)
0.43
0.03
Financial
19.50 4.55
18.65
4.49
1.49 (1,19)
0.24
0.07
Social
27.60 5.63
27.05
6.52
0.15 (1,19)
0.70 0.008
Total Risk
115.70 17.22 115.70 21.64
0.00 (1,19)
1.00
0.00
BART
13.90 3.94
16.8
6.13
5.11 (1,19)
0.03* 0.21
Note. MP = Mean of the placebo group. MT = Mean of the testosterone group. SDP =
Standard deviation of the placebo group. SDT = Standard deviation of the testosterone
group. 2 = partial eta-squared.
*p < 0.05; **p < 0.01; ***p < 0.001
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Table 8
Descriptive Statistics and Within-Subjects Main Effects for Body Self-Esteem Subscales
Descriptive Statistics
Within-Subjects Effects
Outcome:
MP
SDP
MT
SDT
F
df
p-value 2
Placebo vs.
Treatment
PC
32.75 6.54 33.65
5.99
0.70 (1,19)
0.41
0.04
WC
35.05 6.99 35.55
7.66
0.23 (1,19)
0.64
0.01
SA
44.95 6.49 45.85
6.53
1.07 (1,19)
0.31
0.05
Note. MP = Mean of the placebo group. MT = Mean of the testosterone group. SDP =
Standard deviation of the placebo group. SDT = Standard deviation of the testosterone
group. 2 = partial eta-squared.
*p < 0.05; **p < 0.01; ***p < 0.001
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Table 9
Descriptive Statistics and Within-Subjects Main Effects for Mate Value and
Sexual Attitude Variables
Descriptive Statistics
Within-Subjects Effects
Outcome:
MP
SDP
MT
SDT
F
df
p-value 2
Placebo vs.
Treatment
Mate Value
55.00 9.97 57.00
9.94
3.83 (1,19)
0.06
0.17
Sexual
39.50 12.94 39.50 11.06
0.00 (1,19)
1.00
0.00
Attitudes
Note. MP = Mean of the placebo group. MT = Mean of the testosterone group. SDP =
Standard deviation of the placebo group. SDT = Standard deviation of the testosterone
group. 2 = partial eta-squared.
*p < 0.05; **p < 0.01; ***p < 0.001
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Table 10
Descriptive Statistics and Within-Subjects Main Effects for Disgust Sub-Scale Variables
Descriptive Statistics
Within-Subjects Effects
Outcome:
MP
SDP
MT
SDT
F
df
p2
Placebo vs.
value
Treatment
Moral
26.70 7.80 27.45
7.47
0.30 (1,19)
0.59
0.02
Sexual
27.10 10.99 29.10
9.84
2.49 (1,19)
0.13
0.12
Pathogen
26.85 7.54 26.60
6.99
0.06 (1,19)
0.81
0.003
TDDV Moral
28.80 7.97 30.20
5.25
1.45 (1,19)
0.24
0.07
TDDV
28.45 7.65 29.85
8.54
0.68 (1,19)
0.42
0.04
Sexual
TDDV
28.50 9.86 30.20
6.35
2.90 (1,19)
0.11
0.13
Pathogen
Note. MP = Mean of the placebo group. MT = Mean of the testosterone group. SDP =
Standard deviation of the placebo group. SDT = Standard deviation of the testosterone
group. 2 = partial eta-squared.
*p < 0.05; **p < 0.01; ***p < 0.001
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Appendix A: Self-Report Measures
SF-36 Health Survey
1. In general, would you say your health is:
a. Poor
b. Fair
c. Good
d. Very good
e. Excellent
2. Compared to one week ago, how would you rate your health in general now?
a. Much better now than one week ago
b. Somewhat better now than one week ago
c. About the same as one week ago
d. Somewhat worse now than one week ago
e. Much worse now than one week ago
The following questions are about activities you might do during a typical day. Does your
health now limit you in these activities? If so, how much?
3. Vigorous activities, such as running, lifting heavy objects, participating in
strenuous sports.
a. Yes, limited a lot
b. Yes, limited a little
c. No, not limited at all
4. Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling,
or playing golf
a. Yes, limited a lot
b. Yes, limited a little
c. No, not limited at all
5. Lifting or carrying groceries
a. Yes, limited a lot
b. Yes, limited a little
c. No, not limited at all
6. Climbing several flights of stairs
a. Yes, limited a lot
b. Yes, limited a little
c. No, not limited at all
7. Climbing one flight of stairs
a. Yes, limited a lot
b. Yes, limited a little
c. No, not limited at all
8. Bending, kneeling, or stooping
a. Yes, limited a lot
b. Yes, limited a little
c. No, not limited at all
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9. Walking more than a mile
a. Yes, limited a lot
b. Yes, limited a little
c. No, not limited at all
10. Walking several hundred yards.
a. Yes, limited a lot
b. Yes, limited a little
c. No, not limited at all
11. Walking one hundred yards.
a. Yes, limited a lot
b. Yes, limited a little
c. No, not limited at all
12. Bathing or dressing yourself
a. Yes, limited a lot
b. Yes, limited a little
c. No, not limited at all
For the next 4 questions consider the following: during the past week, how much of the
time have you had any of the following problems with your work or other regular daily
activities as a result of your physical health?
13. Cut down on the amount of time you spent on work or other activities.
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
14. Accomplished less than you would like
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
15. Were limited in the kind of work or other activities.
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
16. Had difficulty performing the work or other activities (for example, it took extra
effort).
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
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For the next 3 questions consider the following; during the past week, how much of the
time have you had any of the following problems with your work or regular daily
activities as a result of an emotional problems (such as feeling depressed or anxious)?
17. Cut Down on the amount of time you spent on work or other activities.
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
18. Accomplished less than you would like.
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
19. Did work or other activities less carefully than usual.
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
20. During the past week, to what extent has your physical health or emotional
problems interfered with your normal social activities with family, friends,
neighbors, or groups?
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
21. How much bodily pain have you had during the past week?
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
22. During the past week, how much did pain interfere with your normal work
(including both work outside the home and housework)?
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
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These questions are about how you feel and how things have been with you during the
past week. For each question, please give the one answer that comes closest to the way
you have been feeling. How much of the time during the past week...
23. Did you feel full of life?
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
24. Have you been very nervous?
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
25. Have you felt so down in the dumps that nothing could cheer you up?
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
26. Have you felt calm and peaceful?
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
27. Did you have a lot of energy?
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
28. Have you felt downhearted and depressed?
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
29. Did you feel worn out?
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
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30. Have you been happy?
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
31. Did you feel tired?
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
32. During the past week, how much of the time has your physical health or
emotional problems interfered with your social activities (like visiting with
friends, relatives, etc.)?
a. All of the time.
b. Most of the time.
c. Some of the time.
d. A little of the time
e. None of the time.
How TRUE or FALSE is each of the following statements for you?
33. I seem to get sick a little easier than other people
a. Definitely true.
b. Mostly true.
c. Don’t know.
d. Mostly false.
e. Definitely false.
34. I am as healthy as anybody I know.
a. Definitely true.
b. Mostly true.
c. Don’t know.
d. Mostly false.
e. Definitely false.
35. I expect my health to get worse.
a. Definitely true.
b. Mostly true.
c. Don’t know.
d. Mostly false.
e. Definitely false.
36. My health is excellent.
a. Definitely true.
b. Mostly true.
c. Don’t know.
d. Mostly false.
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e. Definitely false.
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Buss-Perry Aggression Scale Short-Form
Using this 5 point scale, indicate how uncharacteristic or characteristic each of the
following statements is in describing you.
Given enough provocation, I may hit another person.
1. Extremely Uncharacteristic
2. Somewhat Uncharacteristic
Neither
4. Somewhat Characteristic 5. Extremely Characteristic

3.

There are people who pushed me so far that we came to blows.
1. Extremely Uncharacteristic
2. Somewhat Uncharacteristic
Neither
4. Somewhat Characteristic 5. Extremely Characteristic

3.

I have threatened people I know.
1. Extremely Uncharacteristic
2. Somewhat Uncharacteristic
Neither
4. Somewhat Characteristic 5. Extremely Characteristic

3.

I often find myself disagreeing with people.
1. Extremely Uncharacteristic
2. Somewhat Uncharacteristic
Neither
4. Somewhat Characteristic 5. Extremely Characteristic

3.

I can’t help getting into arguments when people disagree with me.
1. Extremely Uncharacteristic
2. Somewhat Uncharacteristic
Neither
4. Somewhat Characteristic 5. Extremely Characteristic

3.

My friends say that I’m somewhat argumentative.
1. Extremely Uncharacteristic
2. Somewhat Uncharacteristic
Neither
4. Somewhat Characteristic 5. Extremely Characteristic

3.

I flare up quickly but get over it quickly.
1. Extremely Uncharacteristic

2. Somewhat Uncharacteristic

60

3.

Neither

4. Somewhat Characteristic

5. Extremely Characteristic

Sometimes I fly off the handle for no good reason .
1. Extremely Uncharacteristic
2. Somewhat Uncharacteristic
Neither
4. Somewhat Characteristic 5. Extremely Characteristic

3.

I have trouble controlling my temper.
1. Extremely Uncharacteristic
2. Somewhat Uncharacteristic
Neither
4. Somewhat Characteristic 5. Extremely Characteristic

3.

At times I feel I have gotten a raw deal out of life.
1. Extremely Uncharacteristic
2. Somewhat Uncharacteristic
Neither
4. Somewhat Characteristic 5. Extremely Characteristic

3.

Other people always seem to get the breaks.
1. Extremely Uncharacteristic
2. Somewhat Uncharacteristic
Neither
4. Somewhat Characteristic 5. Extremely Characteristic

3.

I wonder why sometimes I feel so bitter about things.
1. Extremely Uncharacteristic
2. Somewhat Uncharacteristic
Neither
4. Somewhat Characteristic 5. Extremely Characteristic
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3.

Domain-Specific Risk-Attitude Scale
For each of the following statements, please indicate the likelihood of engaging in each
activity. Provide a rating from 1 to 5, using the following scale:
1

2

Extremely Unlikely

3

4

Not Sure

5
Extremely Likely

Admitting that your tastes are different from those of your friends. (S)
Arguing with a friend who has a very different opinion on an issue. (S)
Asking your boss for a raise. (S)
Betting a day’s income at the horse races. (F)
Buying an illegal drug for your own use. (E)
Chasing a tornado by car to take photos that you can sell to the press. (R)
Cheating a fair amount on your income tax. (E)
Cheating on an exam. (E)
Co-signing a new car loan for a friend. (F)
Dating someone that you are working with. (S)
Deciding to share an apartment with someone you don’t know well. (S)
Disagreeing with your father on a major issue. (S)
Driving home after you had three drinks in the last two hours. (E)
Eating ‘expired’ food products that still ‘look okay’. (H)
Exploring an unknown city or section of town. (R)
Forging somebody’s signature. (E)
Frequent binge drinking. (H)
Going camping in the wild. (R)
Going down a ski run that is too hard or closed. (R)
Going on a safari in Kenya. (R)
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Going on a two-week vacation in a foreign country without booking accommodations
ahead. (R)
Going whitewater rafting at high water in the spring. (R)
Ignoring some persistent physical pain by not going to the doctor. (H)
Illegally copying a piece of software. (E)
Taking a medical drug that has a high likelihood of negative side effects. (H)
Traveling on a commercial airplane. (R)
Plagiarizing a term paper. (E)
Engaging in unprotected sex. (H)
Investing 10% of your annual income in a blue chip stock. (F)
Investing 10% of your annual income in a very speculative stock. (F)
Investing 10% of your annual income in government bonds (treasury bills). (F)
Investing in a business that has a good chance of failing. (F)
Lending a friend an amount of money equivalent to one month’s income. (F)
Moving to a new city. (S)
Never using sunscreen when you sunbathe. (H)
Never wearing a seatbelt. (H)
Not having a smoke alarm in or outside of your bedroom. (H)
Openly disagreeing with your boss in front of your coworkers. (S)
Periodically engaging in a dangerous sport (e.g. mountain climbing or sky diving). (R)
Regularly riding your bicycle without a helmet. (H)
Shoplifting a small item (e.g. a lipstick or a pen). (E)
Smoking a pack of cigarettes per day. (H)
Speaking your mind about an unpopular issue at a social occasion. (S)
Spending money impulsively without thinking about the consequences. (F)
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Stealing an additional TV cable connection. (E)
Taking a day’s income to play the slot-machines at a casino. (F)
Taking a job where you get paid exclusively on a commission basis. (F)
Trying bungee jumping. (R)
Using office supplies for your personal business. (E)
Wearing unconventional clothes. (S)
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Body Esteem-Scale
Instructions: On this page are listed a number of body parts and functions. Please read each
item and indicate how you feel about this part or function of your own body using the
following scale:
A. I have strong negative feelings.
B. I have moderate negative feelings.
C. I have no feelings one way or the other.
D. I have moderate positive feelings.
E. I have strong positive feelings.
1. Body scent.
2. Appetite.
3. Nose.
4. Physical stamina.
5. Reflexes.
6. Lips.
7. Muscular strength.
8. Waist.
9. Energy level.
10. Thighs.
11. Ears.
12. Biceps.
13. Chin.
14. Body build.
15. Physical coordination.
16. Buttocks.
17. Agility.
18. Width of shoulders.
19. Arms.
20. Chest or breasts.
21. Appearance of eyes.
22. Cheeks/cheekbone.
23. Hips.
24. Legs.
25. Figure or physique.
26. Sex drive.
27. Feet.
28. Sex organs.
29. Appearance of stomach.
30. Health.
31. Sex activities.
32. Body hair.
33. Physical condition.
34. Face.
35. Weight.
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Self-Perceived Mating Success Scale
Indicate the degree to which you disagree or agree with each statement below by writing
a number between 1 and 7 in the space provided.
1.
2.
3.
4.
5.
6.
7.

Strongly Disagree
Disagree
Slightly Disagree
Neutral
Slightly Agree
Agree
Strongly Agree

____

Members of the opposite sex often comment that I would make a good
boyfriend/girlfriend.

____

I do not receive many compliments from members of the opposite sex.

____

I am able to attract individuals I find desirable as relationship partners.

____

I receive sexual invitations from members of the opposite sex.

____

I can have as many sexual partners as I choose.

____

I am able to attract individuals I find desirable as sexual partners.

____

Members of the opposite sex that I would like to date, tend to like me back.

____

Members of the opposite sex notice me.

____

I receive many compliments from members of the opposite sex.

____

Members of the opposite sex are not very attracted to me.

____

Members of the opposite sex want to spend time with me and “get to know me.”

____

Members of the opposite sex are attracted to me.
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Three-Domain Disgust Scale
The following items describe a variety of concepts. Please rate how disgusting you find
the concepts described in the items, where 0 means that you do not find the concept
disgusting at all and 6 means that you find the concept extremely disgusting.
1. Shop lifting a candy bar from a convenience store.
2. Hearing two strangers having sex.
3. Stepping on dog poop.
4. Stealing from a neighbor.
5. Performing oral sex.
6. Sitting next to someone who has read sores on their arm.
7. A student cheating to get good grades.
8. Watching a pornographic video.
9. Shaking hand with a stranger who has sweaty palms.
10. Deceiving a friend.
11. Finding out that someone you don’t like has sexual fantasies about you.
12. Seeing some mold on old leftovers in your refrigerator.
13. Forging someone’s signature on a legal document.
14. Bringing someone you just met back to your room to have sex.
15. Standing close to a person who has body odor.
16. Cutting to the front of a line to purchase the last few tickets to a show.
17. A stranger of the opposite sex intentionally rubbing your thigh in an elevator.
18. Seeing a cockroach run across the floor.
19. Intentionally lying during a business transaction.
20. Having anal sex with someone of the opposite sex.
21. Accidently touching a person’s bloody cut.
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Interest in Visual Sexual Stimuli
Attitudes and Beliefs. Please answer each of the following items. Answer as you
feel today, which could be different than how you usually feel. If it helps, imagine what
the item asks about to respond. Use the following scale:
1
2
3
4
5
6
7
Agree Not At All
Very Strongly Agree
___ 1. Seeing attractive people nude doesn’t sexually arouse me.
___ 2. I find the thought of a very attractive body of the opposite sex very exciting.
___ 3. Seeing attractive people (of my preferred sex) in skimpy clothing such as lingerie
or tight briefs would be very sexually exciting to me.
___ 4. The thought of touching a very attractive body of the opposite sex gives me
tingles.
___ 5. Being around an attractive naked body (of my preferred sex) does not sound very
sexually arousing to me.
___ 6. If I met someone I found very attractive right now, I would fantasize about what
they would look like without clothes on.
___ 7. If I were to meet someone especially physically attractive, I may follow them
briefly to get another look.
___ 8. If I were to fantasize about having sex with someone right now, I would try to
picture very vividly in my mind what their body would look like.
___ 9. If I had to choose, right now I’d rather have a long conversation with someone
I’m attracted to than see them naked.
___ 10. Seeing the arm or leg muscles of an attractive opposite-sex person subtly flex
would be a real turn-on right now.
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Appendix B: Testosterone Formulation
Testosterone Pain Study – Methods for
Formulation
Formulation:
Other published work in this area has involved the use of testosterone- cyclodextrin
complexes prepared by processes for which UNM IDS is not equipped. As an alternative,
IDS developed an oil-based testosterone formulation for use in this study. This decision
was made based on the IDS pharmacist’s past experience as a compounding pharmacist,
known chemical properties of testosterone (e.g., it is insoluble in water), and published

formulations such as the following:
Source: Secundum Artem Volume 8 Number 2, “Compounding for Male Andropause”,
available at http://www.perrigo.com/business/pdfs/Sec Artem 8.2.pdf
Note that the final concentration of testosterone in the published formulation is 1 gram
(1,000 mg) in 10 mL oil. At this concentration, the 0.5 mg study dose would occupy a
volume of 0.005 mL, far below the volume that can be accurately delivered sublingually
by a standard oral syringe.
The published formulation was modified for the needs of this study as follows:
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A 0.5 mg dose by this formulation would occupy 0.5 mL, which is acceptable for
sublingual administration. Micronized testosterone USP was used for the active
formulation. Placebo doses were prepared by the same method but without the
testosterone. The silica gel serves as a suspending agent to keep the active ingredient
dispersed throughout the oil base. Silica gel and flavoring were added to both
formulations for blinding purposes. Stevia and a food-grade oil-based clementine
flavoring were selected for the study formulation. Small batches of stock preparation
were prepared ahead of time and doses drawn up on the day of each visit within the
beyond-use dating of each batch.
Chain of Custody: Testosterone is a controlled substance on Schedule III and is
therefore subject to more stringent state and federal regulations than non-controlled
substances. Accordingly, all drug procurement, storage, compounding and dispensation
were conducted under the supervision of a licensed pharmacist in the UNM
Investigational Drug Service Pharmacy (IDS). Each dispensation of study medication
was authorized by a written order signed by a medical doctor on the research team. Strict
adherence to a chain-of-custody plan was maintained throughout the study. Only
authorized researchers, lab personnel and medical personnel had access to study drug at
any time.
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